[3H]Pyridoxine or [3H]pyridoxal in physiological amounts was orally administered to mice and the distribution of isotope between the six recognized forms of vitamin B6 and pyridoxic acid was determined at different times after the administration in the intestine, liver, blood, and brain. After 7min about 50% of the radioactivity in pyridoxine and pyridoxal had been absorbed by the intestine and transported to the blood and other organs. When [3H]pyridoxine was administered, labeled pyri doxal, pyridoxal and pyridoxine-phosphate were found in the intestine and liver, and labeled pyridoxine could not be detected in the peripheral blood but substantial amounts of labeled pyridoxal and pyridoxal phosphate were found in the blood. The time course of the blood [3H]pyridoxal levels following the administration of [3H]pyridoxine was similar to that following the administration of [3H]pyridoxal. These results suggest that the intestine and/or liver play a major role. in converting dietary pyridoxine to circulating pyridoxal which is taken up and phos phorylated by other organs. Moreover, most of the blood [3H]pyridoxal was shown to be located in the plasma. This localization may facilitate utilization by the organs.
(PM) and their phosphorylated forms (PNP, PLP, and PMP), PLP and PMP, the coenzyme forms, are the major B6 compounds in tissues (1) . PN is the form of B6 found in foods from plant sources (2) and is the form most commonly used in vitamin supplements. Therefore, the transport and metabolism of PN to the active coenzyme in the various organs and tissues are important elements in the management of this nutrient.
The general pathway for the metabolic interconversion of B6 vitamers is well 12 T. SAKURAI, T. ASAKURA, and M. MATSUDA known. PN is phosphorylated to PNP by PL kinase which has been detected in all mammalian tissues investigated (3). PNP is converted to PLP by PNP oxidase (4) which, in contrast to the wide distribution of PL kinase, is confined to a few tissues (5, 6). The highest activity of PNP oxidase is found in the liver and intestine with only limited activity in the brain and kidney, but almost no activity in the lung , heart, muscle and pancreas. PLP can be converted to PMP by enzymatic transami nation or to PL by hydrolysis with phosphatases (7). PL is then converted to pyridoxic acid by PL oxidase (6) or again to PLP by PL kinase.
Results from studies of perfused intestine and liver indicate that PN is rapidly taken up by these cells, phosphorylated to PNP by PL kinase and then converted to PLP by PNP oxidase (8, 9). These two enzymes plus phosphatases provide a means of converting dietary PN to PL. In fact, it was found that the PLP newly formed in perfused liver (9) or in isolated hepatocytes (10) was converted to PL and released into the perfusate or the medium. These results suggest that when PN is given as dietary B6, PN may be converted to circulating PL, and the PL may be used as an important source of B6 for most tissues and organs. Further evidence that PL has a transport role was provided by the observation that human plasma PL levels significantly increased in response to PN supplementation (10).
The availability of [3H]B6 vitamers with high specific activity has permitted several experiments that have clarified the processes of transport and metabolism of B6 vitamers in perfused organs (8, 9, 11-13). In this study, a physiological amount of [3H]PN and [3H]PL with a high specific activity was orally administered to mice, and the distribution of isotope among B6 vitamers in various organs including blood was determined to investigate the processes of the transport and metabolism of the vitamers in a whole animal. 
RESULTS
The absorption of [3H]PN by the intestine and the distribution of 3H among B6 vitamers in the organ as a function of time are presented in Fig. la . At 7 min after the oral administration of [3H]PN about half of the isotope in the intestine was absorbed, and labeled PNP, PLP, and PL started to appear in the organ. The amounts of labeled PMP and PM were small as compared with labeled PLP and PL (data not shown).
The distribution of 3H among the B6 vitamers in the liver as a function of time after the [3H]PN administration is illustrated in Fig. l Figure lc shows the distribution of 3H in B6 vitamers in the blood as a function of time after the [3H]PN administration. In contrast to the distribution in the liver , the isotope in the blood was first in PL and secondly in PLP, and was not in PNP and PN. Labeled PL rapidly reached a maximum level after 15min and then diminished somewhat gradually. Most labeled PL in the blood was located in the plasma while about half of labeled PLP was located in the blood cells (Fig. 2a) . Labeled PMP and PM were scarcely found in either the plasma or blood cells. Most labeled PL in the blood was located in the plasma while about half of labeled PLP was located in the blood cells (Fig. 2b) . Labeled PMP and PM were only found in small amounts as compared with labeled PLP and PL. No significant amount of labeled pyridoxic acid was found in the tissues tested following [3H]PN or [3H]PL administration.
DISCUSSION
In a study on vitamin B6 metabolism in animals, it is desirable to administer B6 vitamers with a high specific radioactivity in "trace" amounts to achieve a physiological steady state. The [3H]PN and [3H]PL used in this study had a high specific activity suitable for this purpose.
The present experiment shows that although [3H]PN is rapidly absorbed across the intestinal wall, [3H]PN cannot be found in the circulatory blood. Instead of [3H]PN a noticeable amount of [3H]PL appeared rapidly in the blood (Fig. lc) . These results suggest that PN is completely taken up by the intestine and liver and converted there to PL, and then the product PL is released into the circulatory blood. In fact the isotope of Results from studies of perfused liver (9) or isolated hepatocytes (10) have indicated that PN is rapidly taken up by these cells, converted to PL and then significantly released into the perfusate or the medium. The releases of PL observed in these in vitro experiments seem to reflect the release of PL into the circulatory blood shown in the present experiment. The intestine and liver may provide a means of completely converting dietary PN to circulating PL, which can then serve as a source of the coenzyme PLP in all tissues that contain PL kinase, whether they contain PNP oxidase or not. The results shown in the present report and the observation that human plasma PL levels can markedly increase in response to PN supplementation (10) suggest that in a physiological state PL may have an important transport role between most organs and may be the major source of PLP for these cells.
[3H]PLP found in the brain (Fig. 1d) (Fig. 2 ) suggests that plasma PL may be the major source of PLP for most tissues and that the loose binding of PL to plasma albumin (18) and the resulting accumulation of this vitamer in the plasma may provide a means for PL to function as a principal transport form in the blood (Fig. 4) .
In any case, it is important to note that when a physiological level of PN is orally administered to mice, no PN reaches the circulating system, but PL appears as the predominant form in the circulating blood. In this condition, therefore, all other organs than the intestine and liver are thought not to obtain PN but to obtain PL from the plasma and then to convert it to PLP via PL kinase. Whether [3H]PL found in the blood originated in the intestine or in the liver remains to be clarified in future experiments. We are now proceeding with analyses of [3H]B6 vitamers in portal blood following [3H]PN administration in order to solve this problem (Fig.  4) .
It should be noted that no significant amount of labeled pyridoxic acid is found in the tissues following not only [3H]PN but also [3H]PL administration. A possible explanation for this result might be that pyridoxic acid produced in the tissues does not remain there but is rapidly transported into urine. Assay of labeled B6 vitamers excreted into urine is now in progress.
